Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $166,275 | 10 | 99.9% |
| Food and Beverage | $193.56 | 14 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Orexo US, Inc. | $166,371 | 17 | $0 (2023) |
| GlaxoSmithKline, LLC. | $36.92 | 3 | $0 (2017) |
| Alkermes, Inc. | $18.00 | 1 | $0 (2020) |
| Novo Nordisk Inc | $15.41 | 1 | $0 (2023) |
| Indivior Inc. | $14.38 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.64 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $43,779 | 5 | Orexo US, Inc. ($43,764) |
| 2022 | $119,404 | 4 | Orexo US, Inc. ($119,404) |
| 2021 | $3,122 | 3 | Orexo US, Inc. ($3,108) |
| 2020 | $30.44 | 2 | Alkermes, Inc. ($18.00) |
| 2019 | $35.78 | 3 | Orexo US, Inc. ($35.78) |
| 2018 | $17.78 | 1 | Orexo US, Inc. ($17.78) |
| 2017 | $79.77 | 6 | GlaxoSmithKline, LLC. ($36.92) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/11/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Obesity | ||||||
| 07/10/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $18,378.00 | Research |
| Study: OXD01-001 | ||||||
| 07/10/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: OXD01-001 | ||||||
| 04/13/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $7,974.90 | Research |
| Study: OXD01-001 | ||||||
| 01/26/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $17,036.10 | Research |
| Study: OXD01-001 | ||||||
| 10/06/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $21,220.20 | Research |
| Study: OXD01-001 | ||||||
| 07/13/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $36,615.40 | Research |
| Study: OXD01-001 | ||||||
| 04/21/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $40,796.10 | Research |
| Study: OXD01-001 | ||||||
| 01/14/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $20,771.80 | Research |
| Study: OXD01-001 | ||||||
| 10/14/2021 | Orexo US, Inc. | — | — | Cash or cash equivalent | $607.50 | Research |
| Study: OXD01-001 | ||||||
| 08/19/2021 | Orexo US, Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: OXD01-001 | ||||||
| 08/09/2021 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: OUD | ||||||
| 02/19/2020 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $12.44 | General |
| Category: Addiction Medicine | ||||||
| 01/15/2020 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: CNS | ||||||
| 09/11/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $11.57 | General |
| Category: Addiction Medicine | ||||||
| 05/22/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $10.95 | General |
| Category: Addiction Medicine | ||||||
| 01/30/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $13.26 | General |
| Category: Addiction Medicine | ||||||
| 11/28/2018 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| Category: Addiction Medicine | ||||||
| 05/08/2017 | GlaxoSmithKline, LLC. | BREO (Drug), INCRUSE | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: RESPIRATORY | ||||||
| 04/17/2017 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: Addiction Medicine | ||||||
| 04/03/2017 | GlaxoSmithKline, LLC. | ANORO (Drug), INCRUSE | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: RESPIRATORY | ||||||
| 02/27/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: RESPIRATORY | ||||||
| 02/13/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: RESPIRATORY | ||||||
| 01/25/2017 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $14.69 | General |
| Category: Addiction Medicine | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OXD01-001 | Orexo US, Inc. | $166,275 | 10 |
About Dr. Joseph Campanella, M.D
Dr. Joseph Campanella, M.D is a General Practice healthcare provider based in Kingston, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093853293.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Campanella, M.D has received a total of $166,469 in payments from pharmaceutical and medical device companies, with $43,779 received in 2023. These payments were reported across 24 transactions from 6 companies. The most common payment nature is "" ($166,275).
Practice Information
- Specialty General Practice
- Location Kingston, PA
- Active Since 02/01/2007
- Last Updated 10/22/2010
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093853293
Products in Payments
- Zubsolv (Drug) $96.21
- ANORO (Drug) $24.23
- Vivitrol (Drug) $18.00
- Wegovy (Drug) $15.41
- SUBLOCADE (Drug) $14.38
- BREO (Drug) $12.69
- STIOLTO (Drug) $12.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Kingston
Paul Bushkuhl, Md, MD
General Practice — Payments: $13,848
Dr. Gary Hughes, Dmd, DMD
General Practice — Payments: $3,835
Dr. Downing Moua, D.m.d, D.M.D
General Practice — Payments: $3,631
Dr. Dennis Oppenheimer, D.d.s, D.D.S
General Practice — Payments: $3,588
Britton Hollis, D.d.s, D.D.S
General Practice — Payments: $3,573
Daniel Thacker, D.d.s,P.s, D.D.S,P.S
General Practice — Payments: $2,765